Chiara Recchi

Medicine · Health Sciences

18h-index2.5kcitations64works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(14), Extracellular vesicles in disease(12), Cellular transport and secretion(8), Monoclonal and Polyclonal Antibodies Research(8), Cancer Genomics and Diagnostics(8)

Publications64 total

Correction of glycogen accumulation in muscle, heart and CNS in a pre-clinical model of hematopoietic stem cell gene therapy for Pompe disease
Molecular Genetics and Metabolism·2025
Tu1723 HEMATOPOIETIC STEM CELL GENE THERAPY AS A TREATMENT FOR SEVERE CROHN'S DISEASE ASSOCIATED WITH PATHOGENIC NOD2 GENETIC VARIANTS
Gastroenterology·2024
HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE CROHN’S DISEASE ASSOCIATED WITH NOD2-DEFICIENCY
Inflammatory Bowel Diseases·2024· 1 citedOpen Access
HEMATOPOIETIC STEM CELL GENE THERAPY AS A NOVEL THERAPEUTIC APPROACH FOR SEVERE CROHN’S DISEASE ASSOCIATED WITH NOD2-DEFICIENCY
Gastroenterology·2024· 1 citedOpen Access
OP29 Haematopoietic stem cell gene therapy as a treatment for severe Crohn’s Disease associated with pathogenic NOD2 genetic variants
Journal of Crohn s and Colitis·2024Open Access
Data from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S6 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S1 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S5 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Legends from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S3 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S6 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S4 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S5 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Legends from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S2 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S1 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S2 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
Figure S4 from The Tumor-Suppressor Protein OPCML Potentiates Anti–EGFR- and Anti–HER2-Targeted Therapy in HER2-Positive Ovarian and Breast Cancer
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Hani Gabra(18), Elisa Zanini(16), Jane Antony(16), Miguel C. Seabra(15), Evdoxia Karali(14), Angélique Bobrie(12), Sophie Krumeich(12), Louay Louis(12), Imoh S. Okon(12), Arthur B. McKie(12), Sebastian Vaughan(12), Mona El‐Bahrawy(12), Justin Stebbing(12), Fabien Reyal(11), Luís F. Moita(11), Matías Ostrowski(11), Clotilde Théry(11), Philippe Chavrier(4), Haonan Lu(3), Alistair N. Hume(3)